Related Experiment Video
Updated: Jul 13, 2026

07:24
A Method for Quantifying Upper Limb Performance in Daily Life Using Accelerometers
Published on: April 21, 2017
12.5K
Accelerometer-based measures in Friedreich ataxia: a longitudinal study on real-life activity
Mario Fichera1, Lorenzo Nanetti1, Alessia Monelli1
1Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Frontiers in Pharmacology
|April 3, 2024
Summary
Wearable sensors quantified physical activity changes in Friedreich ataxia (FRDA) patients over one year. Reduced activity correlated with disease progression, showing potential as a trial outcome measure.
Area of Science:
- Neurology
- Biomedical Engineering
- Rehabilitation Science
Background:
- Quantitative physical activity measurement offers insights into daily life for neurological conditions.
- Friedreich ataxia (FRDA) is a rare inherited disease affecting motor function.
Purpose of the Study:
- To evaluate longitudinal changes in physical activity in FRDA patients using wearable sensors.
- To assess the correlation between physical activity, clinical status, and disease progression in FRDA.
Main Methods:
- An observational study involving 26 adult FRDA patients and 13 healthy controls (CTR).
- Participants wore wrist and waist sensors for 7 days at baseline and 1-year follow-up.
- Analysis included time in sedentary/physical activities, Vector Magnitude (VM3), steps/min, and clinical ataxia scales.
Main Results:
- FRDA patients exhibited reduced physical activity compared to controls at baseline.
- Accelerometer measures correlated with clinical scales and disease duration.
- Significant changes in VM3, sedentary time, and Moderate-Vigorous Physical Activity (MVPA) were observed over 1 year.
- Decreased physical activity corresponded with worsened gait scores.
Conclusions:
- Remote monitoring with wearable sensors is feasible and well-tolerated in FRDA patients.
- Accelerometer-based measures objectively quantify disease progression over time in FRDA.
- These data support the use of physical activity monitoring as a complementary outcome in clinical trials.

